Evaluation under field conditions of a rapid test for detection of IgM and igg antibodies against SARS-CoV-2
Keywords:Coronavirus, Validation Studies, Serologic Test, SARS-CoV-2, COVID-19
AbstractObjective. To determine the additional diagnostic performance of a rapid serological test for detection of IgM and IgG antibodies compared to the real-time polymerase chain reaction (RT-PCR) test; for detection of SARS-CoV-2. Methods. A cross-sectional study was carried out including patients hospitalized for COVID-19 in 3 hospitals, health workers exposed to the infection and outpatients who met suspicious case criteria, all of which underwent the molecular test (RT-PCR) and the rapid serological test. The additional diagnostic performance of rapid serological test was evaluated in comparison to molecular tests. Likewise, an approximation was made to the sensitivity and specificity of the rapid serological test. Results. 144 people were included. With the rapid test, 19.4% of positive results were obtained compared to 11.1% in the molecular test (p = 0.03). The rapid serological test detected 21 cases that had been negative by the initial (RT-PCR), providing an additional diagnostic performance of 56.8% compared to the RT-PCR. The additional diagnostic performance was 50.0% during the first week, 70.0% during the second week and 50.0% during the third week of symptom onset. The sensitivity of the rapid serological test was 43.8% and the specificity of 98.9%. Conclusion. The rapid serological test was able to detect a greater number of cases than those detected by the molecular test especially after the second week of onset of symptoms. It also showed high specificity. It is therefore useful as a complementary test to RT-PCR, especially during the second and third week of illness.
Download data is not yet available.
How to Cite
Vidal-Anzardo M, Solis G, Solari L, Minaya G, Ayala-Quintanilla B, Astete-Cornejo J, Luque-Aguilar A, Jorge A, Rojas N, Cardenas F, Soto A. Evaluation under field conditions of a rapid test for detection of IgM and igg antibodies against SARS-CoV-2. Rev Peru Med Exp Salud Publica [nternet]. 2020 Apr. 22 [cited 2023 Mar. 24];37(2):203-9. vailable from: https://rpmesp.ins.gob.pe/index.php/rpmesp/article/view/5534
Copyright (c) 2020 Revista Peruana de Medicina Experimental y Salud Pública
This work is licensed under a Creative Commons Attribution 4.0 International License.